AGA Registry to Expand Understanding of FMT
March 13, 2017
In the March Gastroenterology, the principal investigators describe the registry and how it will fill a critical gap by assessing short- and long-term safety of FMT.
The early adoption and expansion of fecal microbiota transplantation (FMT) in clinical practice and the evolving regulatory framework has left a void in the surveillance of FMT safety and efficacy. AGA's FMT National Registry, funded by the National Institute of Allergy and Infectious Diseases at the NIH (award number R24AI118629), will address this knowledge gap by collecting clinical and patient-reported outcomes.
In the March edition of Gastroenterology the principal investigators of the AGA FMT Registry describe the registry and note that, "these are exciting times; we are just beginning to understand the role of the gut microbiota in health and disease. FMT is a unique case study in which rapid adoption of the clinical practice has preceded the science, and we hope that clinicians and scientists will work together to advance our understanding of the microbiome."
AGA FMT Registry objectives:
- Primary: assess the short-term and long-term safety of FMT and other gut-related microbiota products.
- Secondary: characterizing the effectiveness of FMT and other gut-related microbiota products, gathering information on FMT practice in the U.S., and promoting scientific investigation in FMT and the gut microbiome.
Learn more about this program in the below video featuring the registry's principal investigators.